Australian recommendations for EGFR T790M testing in advanced non-small cell lung cancer.

about

Liquid biomarkers in melanoma: detection and discovery.Evidence-based best practices for EGFR T790M testing in lung cancer in Canada.

P2860

Q47726847-70FF005A-A38C-4F77-983B-AFEFDE929B40 Q54979898-7199D49F-ADB3-49D2-88D6-C58172844C64

P2860

Australian recommendations for EGFR T790M testing in advanced non-small cell lung cancer.

Item

http://www.wikidata.org/entity/Q39430016

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Australian recommendations for EGFR T790M testing in advanced non-small cell lung cancer.

@en

Australian recommendations for EGFR T790M testing in advanced non-small cell lung cancer.

@nl

type

Item

label

Australian recommendations for EGFR T790M testing in advanced non-small cell lung cancer.

@en

Australian recommendations for EGFR T790M testing in advanced non-small cell lung cancer.

@nl

prefLabel

Australian recommendations for EGFR T790M testing in advanced non-small cell lung cancer.

@en

Australian recommendations for EGFR T790M testing in advanced non-small cell lung cancer.

@nl

P1476

Australian recommendations for EGFR T790M testing in advanced non-small cell lung cancer.

@en

P2093

Keith Horwood

http://www.w3.org/2001/XMLSchema#string

Kerryn Garrett

http://www.w3.org/2001/XMLSchema#string

P2860

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.

AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.

Next generation sequencing techniques in liquid biopsy: focus on non-small cell lung cancer patients

Management of dose variability and side effects for individualized cancer pharmacotherapy with tyrosine kinase inhibitors

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma.

Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation.

Establishing the diagnosis of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.

P304

296-303

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/AJCO.12699

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-07-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28699260

http://www.w3.org/2001/XMLSchema#string

Australian recommendations for EGFR T790M testing in advanced non-small cell lung cancer.

about

P2860

P2860

Australian recommendations for EGFR T790M testing in advanced non-small cell lung cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698